Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax<sup>®</sup> compared with Turbuhaler<sup>®</sup> in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain.

Darbà, Josep; Ramírez, Gabriela; García-Rivero, Juan L; Mayoralas, Sagrario; Pascual, José Francisco; Vargas, Diego; Bijedic, Adi

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax^® compared with Turbuhaler^® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain.

Darbà, Josep; Ramírez, Gabriela; García-Rivero, Juan L; Mayoralas, Sagrario; Pascual, José Francisco; Vargas, Diego; Bijedic, Adi.

Afiliación

Darbà J; Department of Economics, Universitat de Barcelona.
Ramírez G; BCN Health Economics & Outcomes Research S.L., Barcelona.
García-Rivero JL; Hospital Laredo, Cantabria.
Mayoralas S; Hospital Ramón y Cajal, Madrid.
Pascual JF; Hospital General Universitario de Alicante, Alicante.
Vargas D; Hospital de Alta Resolución el Toyo, Andalusia.
Bijedic A; Market Access and HEOR Department, TEVA Pharmaceutical, Madrid, Spain.

Clinicoecon Outcomes Res ; 9: 127-137, 2017.

Article en En | MEDLINE | ID: mdl-28228660

Palabras clave

dry powder inhaler; economic evaluation; payers' perspective; region-specific estimates

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Risk_factors_studies Idioma: En Revista: Clinicoecon Outcomes Res Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google